S&P 500   4,234.47 (-1.15%)
DOW   33,779.24 (-0.65%)
QQQ   323.37 (-1.79%)
AAPL   172.42 (-0.99%)
MSFT   286.59 (-1.23%)
META   167.56 (-4.07%)
GOOGL   117.41 (-2.30%)
AMZN   138.53 (-2.65%)
TSLA   886.09 (-2.48%)
NVDA   179.00 (-4.65%)
NIO   19.02 (-4.47%)
BABA   89.32 (-1.56%)
AMD   95.40 (-5.02%)
T   18.42 (-0.05%)
MU   60.75 (-3.54%)
CGC   3.80 (-0.26%)
F   15.85 (-1.86%)
GE   77.56 (-2.08%)
DIS   120.19 (-2.02%)
AMC   18.11 (-6.12%)
PYPL   97.15 (-2.71%)
PFE   49.35 (+1.59%)
NFLX   238.27 (-2.81%)
S&P 500   4,234.47 (-1.15%)
DOW   33,779.24 (-0.65%)
QQQ   323.37 (-1.79%)
AAPL   172.42 (-0.99%)
MSFT   286.59 (-1.23%)
META   167.56 (-4.07%)
GOOGL   117.41 (-2.30%)
AMZN   138.53 (-2.65%)
TSLA   886.09 (-2.48%)
NVDA   179.00 (-4.65%)
NIO   19.02 (-4.47%)
BABA   89.32 (-1.56%)
AMD   95.40 (-5.02%)
T   18.42 (-0.05%)
MU   60.75 (-3.54%)
CGC   3.80 (-0.26%)
F   15.85 (-1.86%)
GE   77.56 (-2.08%)
DIS   120.19 (-2.02%)
AMC   18.11 (-6.12%)
PYPL   97.15 (-2.71%)
PFE   49.35 (+1.59%)
NFLX   238.27 (-2.81%)
S&P 500   4,234.47 (-1.15%)
DOW   33,779.24 (-0.65%)
QQQ   323.37 (-1.79%)
AAPL   172.42 (-0.99%)
MSFT   286.59 (-1.23%)
META   167.56 (-4.07%)
GOOGL   117.41 (-2.30%)
AMZN   138.53 (-2.65%)
TSLA   886.09 (-2.48%)
NVDA   179.00 (-4.65%)
NIO   19.02 (-4.47%)
BABA   89.32 (-1.56%)
AMD   95.40 (-5.02%)
T   18.42 (-0.05%)
MU   60.75 (-3.54%)
CGC   3.80 (-0.26%)
F   15.85 (-1.86%)
GE   77.56 (-2.08%)
DIS   120.19 (-2.02%)
AMC   18.11 (-6.12%)
PYPL   97.15 (-2.71%)
PFE   49.35 (+1.59%)
NFLX   238.27 (-2.81%)
S&P 500   4,234.47 (-1.15%)
DOW   33,779.24 (-0.65%)
QQQ   323.37 (-1.79%)
AAPL   172.42 (-0.99%)
MSFT   286.59 (-1.23%)
META   167.56 (-4.07%)
GOOGL   117.41 (-2.30%)
AMZN   138.53 (-2.65%)
TSLA   886.09 (-2.48%)
NVDA   179.00 (-4.65%)
NIO   19.02 (-4.47%)
BABA   89.32 (-1.56%)
AMD   95.40 (-5.02%)
T   18.42 (-0.05%)
MU   60.75 (-3.54%)
CGC   3.80 (-0.26%)
F   15.85 (-1.86%)
GE   77.56 (-2.08%)
DIS   120.19 (-2.02%)
AMC   18.11 (-6.12%)
PYPL   97.15 (-2.71%)
PFE   49.35 (+1.59%)
NFLX   238.27 (-2.81%)
NASDAQ:AYTU

Aytu BioPharma - AYTU Stock Forecast, Price & News

$0.27
0.00 (-1.55%)
(As of 08/19/2022 01:14 PM ET)
Add
Compare
Today's Range
$0.27
$0.28
50-Day Range
$0.28
$0.70
52-Week Range
$0.26
$3.89
Volume
5,492 shs
Average Volume
1.91 million shs
Market Capitalization
$10.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Aytu BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,907.3% Upside
$5.50 Price Target
Short Interest
Healthy
2.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.66mentions of Aytu BioPharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.05) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

328th out of 1,119 stocks

Pharmaceutical Preparations Industry

151st out of 549 stocks

AYTU stock logo

About Aytu BioPharma (NASDAQ:AYTU) Stock

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Aytu BioPharma Stock Performance

Shares of AYTU Stock remained flat at $0.28 during mid-day trading on Thursday. 1,011,133 shares of the stock were exchanged, compared to its average volume of 839,076. Aytu BioPharma has a 12-month low of $0.26 and a 12-month high of $3.89. The firm's 50 day moving average price is $0.52 and its 200 day moving average price is $0.79. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of 0.30. The stock has a market cap of $10.86 million, a price-to-earnings ratio of -0.07 and a beta of -0.42.

Aytu BioPharma (NASDAQ:AYTU - Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.14. Aytu BioPharma had a negative net margin of 120.24% and a negative return on equity of 41.97%. The company had revenue of $24.20 million during the quarter, compared to the consensus estimate of $24.20 million. As a group, equities analysts expect that Aytu BioPharma will post -1.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on AYTU. Cantor Fitzgerald cut their price objective on Aytu BioPharma from $11.00 to $5.00 in a research report on Tuesday, May 17th. HC Wainwright decreased their price objective on shares of Aytu BioPharma from $11.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, July 21st.

Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AYTU Stock News Headlines

Aytu BioPharma Announces Pricing of Public Offering
Aytu BioPharma: Q3 Earnings Insights
See More Headlines
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AYTU Company Calendar

Last Earnings
11/15/2021
Today
8/19/2022
Next Earnings (Estimated)
9/26/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AYTU
Fax
N/A
Employees
175
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,914.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-58,290,000.00
Net Margins
-120.24%
Pretax Margin
-120.08%

Debt

Sales & Book Value

Annual Sales
$65.63 million
Book Value
$5.47 per share

Miscellaneous

Free Float
37,022,000
Market Cap
$10.70 million
Optionable
Not Optionable
Beta
-0.42

Key Executives

  • Mr. Joshua R. Disbrow (Age 47)
    Chairman & CEO
    Comp: $1.01M
  • Mr. Mark K. Oki CPA (Age 53)
    Chief Financial Officer
  • Mr. Jarrett T. Disbrow Ph.D. (Age 47)
    Exec. VP of Corp. Operations
  • Mr. Greg Pyszczymuka
    Chief Commercial Officer
  • Mr. Topher Brooke
    Exec. VP of Rare Disease Devel.
  • Mr. Russ McMahen
    Sr. VP of R&D













AYTU Stock - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings
or view top-rated stocks.

What is Aytu BioPharma's stock price forecast for 2022?

1 Wall Street research analysts have issued 12-month price targets for Aytu BioPharma's shares. Their AYTU share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 1,883.4% from the stock's current price.
View analysts price targets for AYTU
or view top-rated stocks among Wall Street analysts.

How have AYTU shares performed in 2022?

Aytu BioPharma's stock was trading at $1.35 at the beginning of the year. Since then, AYTU stock has decreased by 79.5% and is now trading at $0.2773.
View the best growth stocks for 2022 here
.

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, September 26th 2022.
View our AYTU earnings forecast
.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its earnings results on Monday, November, 15th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.60. The firm had revenue of $21.90 million for the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 41.97% and a negative net margin of 120.24%. During the same quarter in the prior year, the company earned ($0.40) earnings per share.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

What is Aytu BioPharma's stock symbol?

Aytu BioPharma trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.74%), Millennium Management LLC (0.45%), Prudential Financial Inc. (0.10%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital Master Fund, Armistice Capital, Llc and Joshua R Disbrow.
View institutional ownership trends
.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aytu BioPharma's stock price today?

One share of AYTU stock can currently be purchased for approximately $0.28.

How much money does Aytu BioPharma make?

Aytu BioPharma (NASDAQ:AYTU) has a market capitalization of $10.86 million and generates $65.63 million in revenue each year. The company earns $-58,290,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis.

How many employees does Aytu BioPharma have?

The company employs 175 workers across the globe.

How can I contact Aytu BioPharma?

Aytu BioPharma's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The official website for the company is aytubio.com. The company can be reached via phone at (720) 437-6580 or via email at james@haydenir.com.

This page (NASDAQ:AYTU) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.